Cargando…
Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer’s disease
Although N-truncated Aβ variants are known to be the main constituent of amyloid plaques in the brains of patients with Alzheimer’s disease, their potential as targets for pharmacological intervention has only recently been investigated. In the last few years, the Alzheimer field has experienced a p...
Autores principales: | Bayer, Thomas A., Wirths, Oliver |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4024135/ https://www.ncbi.nlm.nih.gov/pubmed/24803226 http://dx.doi.org/10.1007/s00401-014-1287-x |
Ejemplares similares
-
Synaptic Alterations in Mouse Models for Alzheimer Disease—A Special Focus on N-Truncated Abeta 4-42
por: Dietrich, Katharina, et al.
Publicado: (2018) -
Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X
por: Antonios, Gregory, et al.
Publicado: (2015) -
N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody
por: Antonios, Gregory, et al.
Publicado: (2013) -
N-truncated Aβ(4–x) peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
por: Wirths, Oliver, et al.
Publicado: (2017) -
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases
por: Wirths, Oliver, et al.
Publicado: (2009)